公开(公告)号：EP1991503B1

公开(公告)日：2010-09-08

申请号：EP07711106.0

申请日：2007-02-23

申请人： Ustav Makromolekularni Chemie Akademie Ved Ceske Republiky, v.v.i ,  Ustav Experimentalni Mediciny Akademie Ved Ceske Republiky, v.v.i.

发明人： HORAK, Daniel ,  SYKOVA, Eva ,  BABIC, Michal ,  JENDELOVA, Pavla ,  HAJEK, Milan

IPC分类号： C01G49/08 ,  C01G49/06 ,  A61K49/18 ,  C09C1/24

CPC分类号： C09C1/24 ,  A61K49/1836 ,  A61K49/1845 ,  A61K49/1854 ,  A61K49/1863 ,  A61K49/1872 ,  A61K49/1896 ,  B82Y5/00 ,  B82Y30/00 ,  C01G49/06 ,  C01G49/08 ,  C01P2004/64 ,  C01P2006/42

摘要： The subject of the invention is superparamagnetic nanoparticle probes based on iron oxides, to advantage magnetite or maghemite, with modified surface, coated with mono-, di- or polysaccharides from the group including D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextrans and dextrins, or with amino acids or poly(amino acid)s from the group including alanine, glycine, glutamine, asparagine, histidine, arginine, L-lysine, aspartic and glutamic acid or with synthetic polymers based on (meth)acrylic acid and their derivatives selected from the group containing poly(N,N-dimethylacrylamide), poly(N,N- dimethylmethacrylamide), poly(N, N- diethylacrylamide), poly (N, iV-diethylmethacrylamide), poly(N-isopropylacrylamide), poly(N-isopropylmethacrylamide), which form a colloid consisting of particles with narrow distribution with polydispersity index smaller than 1.3, the average size of which amounts to 0.5-30 nm, to advantage 1-10 nm, the iron content is 70- 99.9 wt.%, to advantage 90 wt.%, the modification agent content 0.1-30 wt.%, to advantage 10 wt.%. The particles of size smaller than 2 nm with polydispersity index smaller than 1.1 can be obtained by a modified method of preparation. Superparamagnetic nanoparticle probes according to the invention are prepared by pre- precipitation of colloidal Fe(OH)3 by the treatment of aqueous 0.1-0.2M solution of Fe(III) salt, to advantage FeCl3, with less than an equimolar amount Of NH4OH, at 21°C, under sonication, to which a solution of a Fe(II) salt, to advantage FeCl2, is added in the mole ratio Fe(III)/Fe(II) = 2 under sonication and the mixture is poured into five- to tenfold, to advantage eightfold, molar excess of 0.5M NH4OH. The mixture is left aging for 0-30 min, to advantage 15 min, and then the precipitate is repeatedly, to advantage 7-10 times, magnetically separated and washed with deionized water. Then 1-3 fold amount, to advantage 1.5 fold amount, relative to the amount of magnetite, of 0.1 M aqueous solution of sodium citrate is added and then, drop wise, 1-3 fold amount, to advantage 1.5 fold amount, relative to the amount of magnetite, of 0.7 M aqueous solution of sodium hypochlorite. The precipitate is repeatedly, to advantage 7-10 times, washed with deionized water under the formation of colloidal maghemite to which, after dilution, is added drop wise, to advantage under 5 -min sonication, an aqueous solution of a modification agent, in the weight ratio modification agent/iron oxide = 0.1-10, to advantage 0.2 for amino acids and poly(amino acid)s and 5 for saccharides. The particles smaller than 2 nm. with polydispersity index smaller than 1.1 are prepared by mixing at 21°C 1 volume part of 10-60 wt. %, to advantage 50 wt.%, of an aqueous solution of a saccharide, disaccharide or polysaccharide, such as D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextran and dextrins, and 1 volume part of aqueous solution of a Fe(II) and Fe(III) salt, to advantage FeCl2 and FeCl3, where the molar ratio Fe(III)/Fe(II) = 2. A 5-15 %, to advantage 7.5 %, solution Of NH4OH is added until pH 12 is attained and the mixture is heated at 60 °C for 15 min. The mixture is then sonicated at 350 W for 5 min and then washed for 24 h by dialysis in water using a membrane with molecular weight cut-off 14,000 until pH 7 is reached. The volume of solution is reduced by evaporation so that the final dry matter content is 50-100 mg/ml, to advantage 80 mg per 1 ml. Superparamagnetic nanoparticle probes according to the invention can be used for labelling cells used in magnetic resonance imaging for monitoring their movement, localization, survival and differentiation especially in detection of pathologies with cell dysfunction and of tissue regeneration and also for labelling and monitoring cells administered for cell therapy purposes, in particular embryo